The above considerations have led to the conclusion that TSLP is a master orchestrator of asthma pathobiology [5,27] and the approval of a monoclonal antibody anti-TSLP (tezepelumab) highly effective in severe asthma treatment [31,32,33]. This evidence concerns the gene TSLP and asthma.